Euroespes S.A. (EEP) - Total Liabilities

Latest as of December 2022: €5.22 Million EUR ≈ $6.10 Million USD

Based on the latest financial reports, Euroespes S.A. (EEP) has total liabilities worth €5.22 Million EUR (≈ $6.10 Million USD) as of December 2022. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Euroespes S.A. cash flow conversion to assess how effectively this company generates cash.

Euroespes S.A. - Total Liabilities Trend (2010–2024)

This chart illustrates how Euroespes S.A.'s total liabilities have evolved over time, based on quarterly financial data. Check Euroespes S.A. (EEP) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Euroespes S.A. Competitors by Total Liabilities

The table below lists competitors of Euroespes S.A. ranked by their total liabilities.

Company Country Total Liabilities
Halfords Group PLC
LSE:HFD
UK GBX675.70 Million
Cre8 Enterprise Limited Class A Ordinary Shares
NASDAQ:CRE
USA $47.14 Million
Codrus Minerals Ltd
AU:CDR
Australia AU$543.91K
Indaptus Therapeutics Inc
NASDAQ:INDP
USA $2.23 Million
International Lithium Corp
V:ILC
Canada CA$306.66K
Inix Technologies Holdings Bhd
KLSE:0094
Malaysia RM23.75 Million
Jet.AI Inc.
NASDAQ:JTAI
USA $3.71 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Euroespes S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Euroespes S.A. market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.77 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.38 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.84 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Euroespes S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Euroespes S.A. (2010–2024)

The table below shows the annual total liabilities of Euroespes S.A. from 2010 to 2024.

Year Total Liabilities Change
2024-12-31 €4.37 Million
≈ $5.11 Million
-13.27%
2023-12-31 €5.04 Million
≈ $5.89 Million
-3.41%
2022-12-31 €5.22 Million
≈ $6.10 Million
+8.20%
2021-12-31 €4.82 Million
≈ $5.64 Million
+13.31%
2020-12-31 €4.26 Million
≈ $4.98 Million
+8.50%
2019-12-31 €3.92 Million
≈ $4.59 Million
-0.94%
2018-12-31 €3.96 Million
≈ $4.63 Million
-17.11%
2017-12-31 €4.78 Million
≈ $5.59 Million
+3.13%
2016-12-31 €4.63 Million
≈ $5.42 Million
+26.95%
2015-12-31 €3.65 Million
≈ $4.27 Million
+1.71%
2014-12-31 €3.59 Million
≈ $4.20 Million
+218.29%
2010-12-31 €1.13 Million
≈ $1.32 Million
--

About Euroespes S.A.

MC:EEP Spain Diagnostics & Research
Market Cap
$4.61 Million
€3.95 Million EUR
Market Cap Rank
#28794 Global
#210 in Spain
Share Price
€0.34
Change (1 day)
+0.00%
52-Week Range
€0.34 - €0.54
All Time High
€1.26
About

Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neu… Read more